Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Torres-Esquius S
- Beas F
- Chen-Liang TH
- Pomares H
- Varela ND
- Hernandez F
- Xicoy B
- Hermosín L
- Arnan M
- Tazón-Vega B
- Blanco A
- Diez-Campelo M
- Lozano ML
- Valcárcel D
- Bosch F
- Montoro MJ
- Jerez A
- GESMD centres
Grupos
Abstract
Patients aged 50 or above diagnosed with myeloid neoplasms (MNs) are typically not candidates for germline testing. However, approximately 8% carry pathogenic germline variants. Allogeneic haematopoietic stem cell transplantation (alloHSCT) remains an option for those aged over 50; neglecting germline testing could mask the risk for relative donor cell-derived MN. We propose a germline-augmented somatic panel (GASP), combining MN predisposition genes with a myeloid somatic panel for timely germline variant identification when initial testing is not indicated. Out of our 133 whole-exome-sequenced MN cases aged over 50 years, 9% had pathogenic/likely variants. GASP detected 92%, compared to 50% with somatic-only panel. Our study highlights the relevance of germline screening in MN, particularly for alloHSCT candidates without established germline-testing recommendations.
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Datos de la publicación
- ISSN/ISSNe:
- 0007-1048, 1365-2141
- Tipo:
- Article
- Páginas:
- 503-509
- DOI:
- 10.1111/bjh.19460
- PubMed:
- 38639421
- Factor de Impacto:
- 1,677 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BRITISH JOURNAL OF HAEMATOLOGY WILEY
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Keywords
- HSC transplantation; genetic testing; germline predisposition; myeloid neoplasms
Campos de Estudio
Cita
Torres S,Beas F,Chen TH,Pomares H,SANTIAGO M,Varela ND,LIQUORI A,Hernandez F,Xicoy B,Hermosín L,Arnan M,Tazón B,Blanco A,CERVERA J,Diez M,Lozano ML,Valcárcel D,Bosch F,Montoro MJ,Jerez A,GESMD C. Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms. Br. J. Haematol. 2024. 205. (2):p. 503-509. IF:3,900. (1).
Portal de investigación